Skip to main content
. 2016 Feb 2;15:10. doi: 10.1186/s12943-016-0495-5

Fig. 5.

Fig. 5

Caki-1 (a) and A-498 (b) cells were treated with the SLC6A3 inhibitor sertraline at 12.5 μM, 25 μM and 50 μM; cell proliferation decreased in a dose-dependent manner